MD3499G2 - Method of differentiated treatment of endometrial cancer - Google Patents

Method of differentiated treatment of endometrial cancer

Info

Publication number
MD3499G2
MD3499G2 MDA20070281A MD20070281A MD3499G2 MD 3499 G2 MD3499 G2 MD 3499G2 MD A20070281 A MDA20070281 A MD A20070281A MD 20070281 A MD20070281 A MD 20070281A MD 3499 G2 MD3499 G2 MD 3499G2
Authority
MD
Moldova
Prior art keywords
level
tryptophanhydroxylase
myometrium
stage
degree
Prior art date
Application number
MDA20070281A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD3499F1 (en
Inventor
Думитру СОФРОНИ
Лилиан ГУЦУ
Катйа ТЕННЕР
Анатол ЧЕРНЫЙ
Корина КАРДАНЮК
Михаил ТОДИРАШ
Майкл БАДЕР
Original Assignee
Общественное Медико-Санитарное Учреждение Онкологический Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общественное Медико-Санитарное Учреждение Онкологический Институт filed Critical Общественное Медико-Санитарное Учреждение Онкологический Институт
Priority to MDA20070281A priority Critical patent/MD3499G2/en
Publication of MD3499F1 publication Critical patent/MD3499F1/en
Publication of MD3499G2 publication Critical patent/MD3499G2/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention refers to medicine, in particular to the gynecologic oncology.Summary of the method of differentiated treatment of endometrial cancer consists in that it is determined the stage of disease, the degree of difference, the level of myometrium invasion, it is determined the level of tryptophanhydroxylase-1. Where the level of tryptophanhydroxylase-1 is above 13,8 conventional units, and to the patients is established the stage of disease IA, IB, the degree of difference 1, 2 and 3, the level of myometrium invasion under 50% or the stage IC, the degree of difference 1 and 2 and the level of myometrium invasion above 50%, it is carried out the total hysterectomy with bilateral salpingo-oophorectomy. Where the level of tryptophanhydroxylase-1 varies from 3,6 up to 13,8 conventional units, after hysterectomy, there are additionally prescribed two courses of chemotherapy with Cysplatinum - 100 mg/m2, drop-by-drop during 4 hours, once to the course and concomitantly it is prescribed the hormonotherapy with Depo-provera - 500 mg, intramuscularly, once a week and the antiestrogentherapy with Tamoxifen - 20 mg/day, the course constituting 3 months with an interval of 3 weeks between courses.
MDA20070281A 2007-10-12 2007-10-12 Method of differentiated treatment of endometrial cancer MD3499G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20070281A MD3499G2 (en) 2007-10-12 2007-10-12 Method of differentiated treatment of endometrial cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20070281A MD3499G2 (en) 2007-10-12 2007-10-12 Method of differentiated treatment of endometrial cancer

Publications (2)

Publication Number Publication Date
MD3499F1 MD3499F1 (en) 2008-02-29
MD3499G2 true MD3499G2 (en) 2008-09-30

Family

ID=39156456

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20070281A MD3499G2 (en) 2007-10-12 2007-10-12 Method of differentiated treatment of endometrial cancer

Country Status (1)

Country Link
MD (1) MD3499G2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2547569C1 (en) * 2014-02-03 2015-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method of treating patients suffering locally advanced cervical cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD186C2 (en) * 1994-03-01 1995-09-30 Etco Ludmila Method of endometritis treatment after cesarean section
MD2377G2 (en) * 2003-09-18 2004-08-31 Институтул Де Черчетэрь Штиинцифиче Ын Домениул Окротирий Сэнэтэуий Мамей Ши Копилулуй Ал Министерулуй Сэнэтэций Method of treatment of puerperal endometritis
MD3222G2 (en) * 2006-03-22 2007-08-31 Общественное Медико-Санитарное Учреждение Онкологический Институт Method of endometrial cancer diagnosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD186C2 (en) * 1994-03-01 1995-09-30 Etco Ludmila Method of endometritis treatment after cesarean section
MD2377G2 (en) * 2003-09-18 2004-08-31 Институтул Де Черчетэрь Штиинцифиче Ын Домениул Окротирий Сэнэтэуий Мамей Ши Копилулуй Ал Министерулуй Сэнэтэций Method of treatment of puerperal endometritis
MD3222G2 (en) * 2006-03-22 2007-08-31 Общественное Медико-Санитарное Учреждение Онкологический Институт Method of endometrial cancer diagnosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Huntsman D.G., Clement P.B., Gilks C.B., Scully R.E. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am. J. Surg. Pathol. Nr. 18, 1994, p. 364-375 *

Also Published As

Publication number Publication date
MD3499F1 (en) 2008-02-29

Similar Documents

Publication Publication Date Title
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2016006119A (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-py rido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer.
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
MX367341B (en) TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE.
MX2014010590A (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders.
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
UA85702C2 (en) 3-[4-heterocyclyl -1,2,3,-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
MX2014002967A (en) Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
WO2012078633A3 (en) Methods of inhibiting metastasis from cancer
MX362855B (en) Quinazolinone derivatives as parp inhibitors.
TW200603804A (en) Treatment with irinotecan (cpt-11) and an EGFR-inhibitor
JP2016525097A5 (en)
MX360554B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2.
MY161288A (en) Combination anti - cancer therapy
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
IN2015DN00528A (en)
MX2022011372A (en) Zinc-î³-pga compositions and methods for treating cancer.
PL1732926T3 (en) Mitotic kinesin inhibitors
NZ598171A (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
WO2011066082A3 (en) Markers associated with ribavirin-induced anemia
MD3499G2 (en) Method of differentiated treatment of endometrial cancer

Legal Events

Date Code Title Description
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees